1
|
Tuft C, Maheepala K, Raguparan A, Naeem A, Lodh S, Lindstrom S. Pulmonary artery sarcoma: An important mimic of pulmonary embolism-Case reports and literature review. Respirol Case Rep 2022; 10:e0897. [PMID: 35028154 PMCID: PMC8743422 DOI: 10.1002/rcr2.897] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2021] [Revised: 11/27/2021] [Accepted: 12/06/2021] [Indexed: 11/10/2022] Open
Abstract
Pulmonary artery intimal sarcoma (PAIS) is a rare malignancy which closely mimics acute or chronic pulmonary thromboembolism. There are clinical and radiological characteristics which may raise suspicion of this important differential diagnosis. These include disproportionately low d-dimer, troponin T or NT-proBNP, as well as characteristic findings on CT pulmonary angiography such as the 'wall eclipsing sign' and an non-dependent position of filling defects in the large arteries. Prompt diagnosis avoids inappropriate anticoagulation and facilitates early surgical management which may improve prognosis. There is emerging evidence of an effective treatment paradigm with surgical resection and adjuvant chemotherapy. We present two cases of PAIS diagnosed at a single centre within a 2-year period. We review the literature and demonstrate the features at presentation in our cases which were suggestive of the diagnosis.
Collapse
Affiliation(s)
- Colin Tuft
- Respiratory and Sleep Medicine DepartmentSt George HospitalSydneyNew South WalesAustralia
| | - Krishan Maheepala
- Respiratory and Sleep Medicine DepartmentSt George HospitalSydneyNew South WalesAustralia
| | - Ajantha Raguparan
- Respiratory and Sleep Medicine DepartmentSt George HospitalSydneyNew South WalesAustralia
| | - Anas Naeem
- Intensive Care UnitSt George HospitalSydneyNew South WalesAustralia
| | - Suhrid Lodh
- Radiology DepartmentSt George HospitalSydneyNew South WalesAustralia
| | - Steven Lindstrom
- Respiratory and Sleep Medicine DepartmentSt George HospitalSydneyNew South WalesAustralia
| |
Collapse
|
2
|
Li J, Liu L, Song LX, Zhang YH, Liu Y, Gu S, Wang JF, Huang Q, Ma ZH, Guo XJ, Yang MF, Jiang W, Li F, Yang YH. Clinical Features and Outcomes of Pulmonary Artery Sarcoma. Heart Lung Circ 2021; 31:230-238. [PMID: 34417115 DOI: 10.1016/j.hlc.2021.06.448] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Revised: 05/28/2021] [Accepted: 06/08/2021] [Indexed: 01/27/2023]
Abstract
OBJECTIVES A retrospective cohort study was designed to describe the clinical features and outcomes of pulmonary artery sarcoma (PAS). METHODS Twenty-two (22) consecutive patients diagnosed with PAS by pathological examination were enrolled and followed up until they died or until January 2020. The medical records were retrospectively reviewed to evaluate the clinical characteristics, image findings, and outcomes. RESULTS 1) Twenty-one (21, 95.5%) patients were firstly misdiagnosed. Dyspnoea was the most common presenting symptom (19 of 22, 86.4%). 2) Filling defects in the right pulmonary artery were seen in 17 patients (77.3%) with computed tomography pulmonary angiography or magnetic resonance pulmonary angiography. Among those patients, 14 underwent positron emission tomography-computed tomography detection and 13 (92.9%) were found to have increased uptake value in the pulmonary artery. 3) The median survival (from diagnosis to death or January 2020) of the total series was 11.6 months (range, 0.7-68.5 months). The estimated cumulative survival rates at 1, 2, and 3 years were 52.6%, 32.8%, and 19.7%, respectively. Patients who received surgery and/or chemo-radiotherapy treatment had a better survival rate compared with patients without treatment (the estimated cumulative survival rates at 1, 2, and 3 years were 60.3%, 39.1%, and 29.3%, respectively, vs 33.3%, 16.6%, and 0, accordingly) and better survival time (median survival 17.02 vs 3.16 months, respectively) (p=0.025). CONCLUSIONS Pulmonary artery sarcoma is easily misdiagnosed, as the symptoms and routine image detection are nonspecific. Positron emission tomography-computed tomography may be helpful in diagnosis. Surgery and/or chemo-radiotherapy offer a chance for better outcomes.
Collapse
Affiliation(s)
- Jifeng Li
- Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China; Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China; Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China; Department of Respiratory Disease, Capital Medical University, Beijing, P. R. China. https://twitter.com/JifengLi5
| | - Lin Liu
- Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China; Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China; Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China; Department of Respiratory Disease, Capital Medical University, Beijing, P. R. China
| | - Ling-Xie Song
- Department of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China
| | - Yu-Hui Zhang
- Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China; Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China; Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China; Department of Respiratory Disease, Capital Medical University, Beijing, P. R. China
| | - Yan Liu
- Department of Cardiac Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China
| | - Song Gu
- Department of Cardiac Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China
| | - Jian-Feng Wang
- Department of Interventional Radiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China
| | - Qiang Huang
- Department of Interventional Radiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China
| | - Zhan-Hong Ma
- Department of Radiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China
| | - Xiao-Juan Guo
- Department of Radiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China
| | - Min-Fu Yang
- Department of Nuclear Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China
| | - Wei Jiang
- Department of Echocardiography, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China
| | - Feng Li
- Department of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China
| | - Yuan-Hua Yang
- Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China; Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China; Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China; Department of Respiratory Disease, Capital Medical University, Beijing, P. R. China.
| |
Collapse
|
3
|
Altshuler E, Lowther G, Jantz M. Primary Pulmonary Artery Sarcoma Confined to the Left Pulmonary Artery. J Investig Med High Impact Case Rep 2021; 9:23247096211014687. [PMID: 33969719 PMCID: PMC8113362 DOI: 10.1177/23247096211014687] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Primary pulmonary artery sarcomas (PPAS) are extremely rare tumors that are often mislabeled as pulmonary emboli (PE). PPAS usually involve the pulmonary trunk and are histologically classified as leiomyosarcoma, spindle cells sarcoma, fibrous histiocytoma, or undifferentiated sarcoma. Our case involved a 78-year-old man with an undifferentiated PPAS confined to the left pulmonary artery that was initially misdiagnosed as a PE. After a month-long delay in treatment in which the patient was prescribed warfarin, the correct diagnosis was made. Pulmonary artery endarterectomy and left lung pneumonectomy were performed, and he survived for 18 months before disease recurrence and death. Our case helps illustrate some of the clinical and radiographic findings that help distinguish PPAS from PE.
Collapse
|
4
|
Henick BS, Ingham M, Shirazi M, Marboe C, Turk A, Hsiao S, Mansukhani MM. Assay Complementarity to Overcome False-Negative Testing for Microsatellite Instability/Mismatch Repair Deficiency: A Pembrolizumab-Sensitive Intimal Sarcoma. JCO Precis Oncol 2020; 4:570-574. [DOI: 10.1200/po.19.00351] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Brian S. Henick
- Department of Medicine, Medical Oncology, Columbia University Irving Medical Center, New York City, NY
| | - Matthew Ingham
- Department of Medicine, Medical Oncology, Columbia University Irving Medical Center, New York City, NY
| | - Maryam Shirazi
- Department of Pathology, Molecular Pathology, Columbia University Irving Medical Center, New York City, NY
| | - Charles Marboe
- Department of Pathology, Molecular Pathology, Columbia University Irving Medical Center, New York City, NY
| | - Andrew Turk
- Department of Pathology, Molecular Pathology, Columbia University Irving Medical Center, New York City, NY
| | - Susan Hsiao
- Department of Pathology, Molecular Pathology, Columbia University Irving Medical Center, New York City, NY
| | - Mahesh M. Mansukhani
- Department of Pathology, Molecular Pathology, Columbia University Irving Medical Center, New York City, NY
| |
Collapse
|
5
|
Wang J, Li TL, Zheng S. A primary pulmonary artery sarcoma associated with multiple lesions. World J Emerg Med 2020; 11:270-273. [PMID: 33014227 DOI: 10.5847/wjem.j.1920-8642.2020.04.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Jing Wang
- Department of Geriatric, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
| | - Tian-Lang Li
- Department of Geriatric, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
| | - Shu Zheng
- Institution of Tumor, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
| |
Collapse
|
6
|
Xu R, Zhao Y, Xu X, Liu S, Hu C, Lv D, Wu H. Pulmonary intimal sarcoma involving the pulmonary valve and right ventricular outflow tract: A case report and literature review. Medicine (Baltimore) 2020; 99:e18813. [PMID: 32011489 PMCID: PMC7220449 DOI: 10.1097/md.0000000000018813] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Revised: 11/19/2019] [Accepted: 12/18/2019] [Indexed: 01/22/2023] Open
Abstract
INTRODUCTION Pulmonary artery intimal sarcoma (PAIS) is a rare and highly aggressive tumor, and approximately 80% of pulmonary cases occur in the pulmonary trunk. We report herein a case of retrograde extension of the sarcoma to the pulmonary valve and right ventricle, which is an uncommon manifestation of this lethal tumor. PATIENT CONCERNS A 41-year-old woman was initially diagnosed with pulmonary thromboembolism (PTE) and transferred to our hospital. DIAGNOSIS Computed tomographic pulmonary angiography (CTPA) showed that there are low-density filling defects in both pulmonary arteries, and the patient was diagnosed with PTE. However, the ultrasonographers considered that the lesion is a space-occupying type that involves the right ventricular outflow tract and pulmonary valve instead of PTE. Postoperative pathology confirmed the diagnosis of PAIS. INTERVENTIONS The patient underwent resection of pulmonary artery sarcoma and endarterectomy. OUTCOMES During the follow-up via telephone 1 month after discharge, the patient reported to have been feeling well. CONCLUSION Owing to the rarity of the disease and its non-specific clinical manifestations, approximately half of the PAIS cases are misdiagnosed or have a delayed diagnosis. Thus, improving our understanding of the disease and facilitating its early diagnosis are essential.
Collapse
Affiliation(s)
- Rui Xu
- Department of Ultrasonography, Second Hospital of Jilin University
| | - Yixuan Zhao
- Department of Ultrasonography, Second Hospital of Jilin University
| | - Xiaosen Xu
- Department of Ultrasonography, Changchun Traditional Chinese, Medicine Hospital, Changchun, Jilin, China
| | - Shuang Liu
- Department of Ultrasonography, Second Hospital of Jilin University
| | - Chenyu Hu
- Department of Ultrasonography, Second Hospital of Jilin University
| | - Dongmei Lv
- Department of Ultrasonography, Second Hospital of Jilin University
| | - Huiying Wu
- Department of Ultrasonography, Second Hospital of Jilin University
| |
Collapse
|
7
|
Al-Mehisen R, Al-Halees Z, Alnemri K, Al-Hemayed W, Al-Mohaissen M. Primary pulmonary artery sarcoma: A rare and overlooked differential diagnosis of pulmonary embolism. Clues to diagnosis. Int J Surg Case Rep 2019; 65:15-19. [PMID: 31675686 PMCID: PMC6838465 DOI: 10.1016/j.ijscr.2019.10.014] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2019] [Revised: 10/05/2019] [Accepted: 10/08/2019] [Indexed: 12/31/2022] Open
Abstract
PPAS is an aggressive malignant tumor that masquerades as PE leading to a delay in diagnosis. Limited data exist on the clinical presentation, diagnosis, and management of PPAS. Knowledge of the clinical and imaging characteristics of this tumor is of importance for clinicians and surgeons. Early definitive surgery may improve survival; early diagnosis aided by imaging studies improves surgical outcomes.
Introduction Primary pulmonary artery sarcoma (PPAS) is a very rare tumor that mimics pulmonary embolism (PE) in clinical presentation and on imaging studies, therefore leading to diagnostic delay and increased patient mortality. Presentation of case We discuss the case of 37-year-old man with a rapidly progressing PPAS, which was initially managed as PE. Imaging studies, particularly computed tomography and magnetic resonance imaging, were helpful in reaching the correct diagnosis. Because of the dismal prognosis of such cases, which improves by definite surgery, the patient underwent extensive surgical resection which got complicated by pulmonary reperfusion injury and intrapulmonary hemorrhage, and thus died. Discussion Owing to the rarity of the tumor, PPAS is often initially mistakenly diagnosed as PE, leading to a diagnostic delay and increased mortality. Having a high index of suspicion in “atypical PE” cases and a knowledge of the characteristic radiological and clinical features of PPAS may expedite the diagnosis and improve survival. Pulmonary artery distension by the mass on imaging studies and compression of neighboring structures are in favor of a tumor rather than PE. Additionally, tissue characterization on magnetic resonance imaging is particularly useful in differentiating tumor from PE. PPAS has a very poor prognosis which improves by early definitive surgery. Perioperative and late mortality however, remain high. Conclusions Physicians should be alert of this tumor despite its rarity because diagnostic delay increases mortality. In this report, we summarize the features that differentiate PPAS from PE and the importance of imaging in diagnosing the tumor.
Collapse
Affiliation(s)
- Rabah Al-Mehisen
- Department of Cardiology, Security Forces Hospital, Riyadh 11481, Saudi Arabia
| | - Zohair Al-Halees
- Cardiac Surgery Section, King Faisal Heart Centre, King Faisal Specialist Hospital & Research Centre, Riyadh 12713, Saudi Arabia
| | - Khalid Alnemri
- Department of Cardiology, Security Forces Hospital, Riyadh 11481, Saudi Arabia
| | - Waleed Al-Hemayed
- Department of Cardiology, King Faisal Specialist Hospital & Research Center, Riyadh 12713, Saudi Arabia
| | - Maha Al-Mohaissen
- Department of Clinical Sciences, Cardiology, Princess Nourah Bint Abdulrahman University, Riyadh 11671, Saudi Arabia; Princess Nourah Bint Abdulrahman University Cardiovascular Disease in Women Research Chair, Riyadh, Saudi Arabia.
| |
Collapse
|
8
|
Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R, Teterycz P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desar I, Fedenko A, Maki RG, Jones RL, Benjamin RS, Blay JY, Kawai A, Gounder M, Gronchi A, Le Cesne A, Mir O, Czarnecka AM, Schuetze S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A, Mariani L, Casali PG, Thornton K, Stacchiotti S. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer 2019; 126:98-104. [PMID: 31536651 DOI: 10.1002/cncr.32508] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Revised: 06/22/2019] [Accepted: 07/08/2019] [Indexed: 11/09/2022]
Abstract
BACKGROUND Intimal sarcoma (InS) is an exceedingly rare neoplasm with an unfavorable prognosis, for which new potentially active treatments are under development. We report on the activity of anthracycline-based regimens, gemcitabine-based regimens, and pazopanib in patients with InS. METHODS Seventeen sarcoma reference centers in Europe, the United States, and Japan contributed data to this retrospective analysis. Patients with MDM2-positive InS who were treated with anthracycline-based regimens, gemcitabine-based regimens, or pazopanib between October 2001 and January 2018 were selected. Local pathological review was performed to confirm diagnosis. Response was assessed by RECIST1.1. Recurrence-free survival (RFS), progression-free survival (PFS) and overall survival were computed by Kaplan-Meier method. RESULTS Seventy-two patients were included (66 anthracycline-based regimens; 26 gemcitabine-based regimens; 12 pazopanib). In the anthracycline-based group, 24 (36%) patients were treated for localized disease, and 42 (64%) patients were treated for advanced disease. The real-world overall response rate (rwORR) was 38%. For patients with localized disease, the median RFS was 14.6 months. For patients with advanced disease, the median PFS was 7.7 months. No anthracycline-related cardiac toxicity was reported in patients with cardiac InS (n = 26). For gemcitabine and pazopanib, the rwORR was 8%, and the median PFS was 3.2 and 3.7 months, respectively. CONCLUSION This retrospective series shows the activity of anthracycline-based regimens in InS. Of note, anthracyclines were used in patients with cardiac InS with no significant cardiac toxicity. The prognosis in patients with InS remains poor, and new active drugs and treatment strategies are needed.
Collapse
Affiliation(s)
- Anna Maria Frezza
- Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale Tumori, Milan, Italy
| | - Tarek Assi
- Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France
| | - Salvatore Lo Vullo
- Unit of Clinical Epidemiology and Trial Organization, IRCCS Fondazione Istituto Nazionale Tumori, Milan, Italy
| | - Eytan Ben-Ami
- Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Armelle Dufresne
- Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France
| | - Kan Yonemori
- Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Emi Noguchi
- Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Brittany Siontis
- Department of Medicine, University of Michigan, Ann Arbor, Michigan
| | - Richard Ferraro
- Department of Medicine, Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Pawel Teterycz
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland
| | - Florence Duffaud
- Department of Medical Oncology, La Timone University Hospital, Aix-Marseille Université, Marseille, France
| | - Vinod Ravi
- Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Bruno Vincenzi
- Department of Medical Oncology, Università Campus Bio-Medico di Roma, Rome, Italy
| | - Hans Gelderblom
- Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands
| | - Maria A Pantaleo
- Department of Specialized, Experimental and Diagnostic Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - Giacomo G Baldi
- Department of Medical Oncology, Nuovo Ospedale "S. Stefano,", Prato, Italy
| | - Ingrid Desar
- Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Alexander Fedenko
- Department of Medical Oncology, N. N. Blokhin Russian Cancer Research, Moscow, Russian Federation
| | - Robert G Maki
- Medical Oncology, Northwell Cancer Institute and Cold Spring Harbor Laboratory, Long Island, New York
| | - Robin L Jones
- Sarcoma Unit, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, London, United Kingdom
| | - Robert S Benjamin
- Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Jean Yves Blay
- Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France
| | - Akira Kawai
- Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Mrinal Gounder
- Department of Medicine, Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Alessandro Gronchi
- Sarcoma Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - Axel Le Cesne
- Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France
| | - Olivier Mir
- Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France
| | - Anna M Czarnecka
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland
| | - Scott Schuetze
- Department of Medicine, University of Michigan, Ann Arbor, Michigan
| | - Andrew J Wagner
- Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Julien Adam
- Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France
| | - Marta Barisella
- Department of Diagnostic Pathology and Laboratory Medicine, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy
| | | | - Jason L Hornick
- Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| | | | - Luigi Mariani
- Unit of Clinical Epidemiology and Trial Organization, IRCCS Fondazione Istituto Nazionale Tumori, Milan, Italy
| | - Paolo G Casali
- Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale Tumori, Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| | - Katherine Thornton
- Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Silvia Stacchiotti
- Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale Tumori, Milan, Italy
| |
Collapse
|
9
|
Chiola I, Belgioia L, Vaccara EML, Gusinu M, Corvò R. Reirradiation of pulmonary artery intimal sarcoma: A case report. Clin Case Rep 2019; 7:1342-1346. [PMID: 31360482 PMCID: PMC6637327 DOI: 10.1002/ccr3.2216] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Revised: 04/02/2019] [Accepted: 05/05/2019] [Indexed: 11/23/2022] Open
Abstract
We report here the case of a patient with 4 years long-term survival after treatment with surgery, chemotherapy, and radiotherapy with good local control. This case highlights the possible role of radiation therapy in this tumor.
Collapse
Affiliation(s)
- Ilaria Chiola
- Health Science Department (DISSAL)University of GenoaGenoaItaly
| | - Liliana Belgioia
- Health Science Department (DISSAL)University of GenoaGenoaItaly
- Radiation Oncology DepartmentIRCCS San Martino HospitalGenoaItaly
| | | | - Marco Gusinu
- Medical Physics DepartmentIRCCS San Martino HospitalGenoaItaly
| | - Renzo Corvò
- Health Science Department (DISSAL)University of GenoaGenoaItaly
- Radiation Oncology DepartmentIRCCS San Martino HospitalGenoaItaly
| |
Collapse
|
10
|
Noguchi T, Gomi D, Fukushima T, Ozawa T, Kobayashi T, Sekiguchi N, Mamiya K, Koizumi T. A Case of Unresectable Pulmonary Artery Intimal Sarcoma with Prolonged Survival by Chemotherapy. Case Rep Oncol 2019. [DOI: 10.1159/000496334] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Pulmonary artery intimal sarcoma is a rare malignant tumor. Due to its low prevalence, little is known about efficacious systemic chemotherapies in cases where the tumors are unresectable or metastatic. In addition, the location of the disease can contribute to poor survival regardless of the response to therapy, as the tumor’s position can cause pulmonary artery hypertension either rapidly or chronically. We encountered a case of unresectable pulmonary artery intimal sarcoma with lung metastases. Treatment with several cytotoxic agents resulted in prolonged survival of 14.2 months. Here, we report the clinical course of this case and present a review of the relevant literature.
Collapse
|